help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on July 13, 2006, doi:10.1164/rccm.200603-380OC

Am. J. Respir. Crit. Care Med., Volume 174, Number 9, November 2006, 990-996

A more recent version of this article appeared on November 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200603-380OCv1
174/9/990    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abroug, F.
Right arrow Articles by Knani, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abroug, F.
Right arrow Articles by Knani, J.

Submitted on March 15, 2006
Accepted on July 13, 2006

Left Heart Dysfunction and Severe Exacerbation of COPD: Diagnostic Performance of Cardiac Biomarkers

Fekri Abroug1*, Lamia Ouanes-Besbes1, Noureddine Nciri1, Noura Sellami1, Faouzi Addad2, Khaldoun Ben Hamda2, Adel Ben Amor3, Mohamed F Najjar3, and Jalel Knani1

1 Intensive Care Unit, CHU F.Bourguiba, Monastir, Tunisia, 2 Department of Cardiology, CHU F.Bourguiba, Monastir, Tunisia, 3 Biochemistry Laboratory, CHU F.Bourguiba, Monastir, Tunisia

* To whom correspondence should be addressed. E-mail: f.abroug{at}rns.tn.

Rationale : cardiac biomarkers have good performance to distinguish acute dyspnea due to left heart dysfunction from that of pulmonary origin. However, they have not been assessed in the specific setting of acute exacerbation of COPD (AECOPD) where they might be released without left heart impairment. Objectives: to assess the accuracy of Troponin T and NT-proBNP dosage in the diagnosis of AECOPD associated with left ventricular (LV) dysfunction. Methods: both biomarkers were measured in 148 consecutive patients upon ICU admission for AECOPD. A panel of physicians adjudicated blindly the cause of AECOPD to be unlikely, possibly or definitely associated with LV dysfunction. Measurements and main results: the final diagnosis was AECOPD definitely associated with acute left heart dysfunction in 31.1%, possibly associated with LV dysfunction in 13.5% and unlikely associated with LV dysfunction in 55.4%. Both NT-proBNP and Troponin T levels were statistically different among the three groups. The area under receiver-operating-characteristics curve was greater for NT-proBNP (0.95 vs 0.67). A cut-off of 1000pg/ml was accurate to rule-out left heart involvement in AECOPD (sensitivity: 94%, negative predictive value: 94%, negative likelihood ratio=0.08). A cut-off of 2500pg/ml had the best operating characteristics to rule-in the diagnosis (positive likelihood ratio: 5.16). Left heart involvement in AECOPD was the only variable independently associated with an increased secretion of NT-proBNP (Odds ratio: 74; 95%CI: 15-375; p=0.0001). Conclusion: NT-proBNP and Troponin T are useful in excluding AECOPD associated with left ventricular dysfunction. NT-proBNP was more accurate.


Key words: COPD, exacerbation, BNP, Troponin, left ventricular dysfunction




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
N. MacIntyre and Y. C. Huang
Acute Exacerbations and Respiratory Failure in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 530 - 535.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. F. Rabe, B. Beghe, F. Luppi, and L. M. Fabbri
Update in Chronic Obstructive Pulmonary Disease 2006
Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1222 - 1232.
[Full Text] [PDF]


Home page
ChestHome page
G. B. J. Mancini
Clarion Call for Trials Assessing "Cardiopulmonary" Agents To Reduce Morbidity and Mortality in Inflammatory Lung Diseases
Chest, April 1, 2007; 131(4): 950 - 951.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. Ceconi and R. Ferrari
One heart, two lungs together forever.
Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 962 - 963.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society